Ivan Bessonov, CTO and cofounder of Efferon, presented the results at NEPHROLOGIE 2025 Congress in Berlin. The study measured blood levels of three antibiotic drugs during Efferon LPS hemoadsorption in sepsis patients.

Physicians prescribing extracorporeal treatment in sepsis need to know if antibiotics are affected. Should the dosages be adjusted? For Efferon LPS, we now have data.

Eight study centers. Thirty sepsis patients. Three antibiotics with vastly different pharmacokinetics.

Results: 5% of vancomycin, 12% of meropenem, and 20% of linezolid were removed during four hours of hemoadsorption following the drug infusion. These values represent upper bounds for dose compensation.

In pharmacokinetic terms: Efferon LPS contributed 11% to vancomycin clearance, 25% to meropenem clearance, and 36% to linezolid clearance. By EXTRIP criteria, vancomycin is non-dialyzable while meropenem and linezolid are slightly dialyzable.

The study recommends therapeutic drug monitoring during HA treatment. Dose adjustments depend on the patient’s condition, concomitant therapies, device exposure time, and timing of drug administration.

Efferon LPS is a next-generation extracorporeal blood adsorber, manufactured in the EU and approved for use in sepsis patients under MDR regulation in 31 countries.

Efferon LPS is available in Germany as HEMATOPURE DUO by our partner Diamed.